Prostate cancer clinical trials

Explore recruiting prostate cancer clinical trials.

Recruiting prostate cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Prostate cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

C3441052 - TALAPRO-3: A Phase 3, Randomized, Double-Blind Study of Talazoparib with Enzalutamide Versus Placebo with Enzalutamide in Men with DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer

Czechia, Slovakia, Belgium, Italy, Finland, Germany +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)

Belgium, Spain, Poland, Italy, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

ECETEP : Pilot study evaluating PSMA positron emission tomography for monitoring clinically significant prostate cancer after focal HIFU treatment

France

Therapeutic use (Phase IV) EU CTIS Study details

Add-Aspirin: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non metastatic solid tumours.

Ireland

Therapeutic confirmatory (Phase III) EU CTIS Study details

SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment

Sweden, Netherlands, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

CARLHA-2_AN OPEN LABEL, RANDOMIZED, PHASE III STUDY EVALUATING THE EFFICACY OF ACOMBINATION OF APALUTAMIDE WITH RADIOTHERAPY AND LHRH AGONIST IN HIGH-RISK POST-PROSTATECTOMY BIOCHEMICALLY RELAPSED PROSTATE CANCER PATIENTS

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Prostate cancer trials by city

Prostate cancer in Toronto Prostate cancer in Vancouver Prostate cancer in Montreal Prostate cancer in Calgary Prostate cancer in Edmonton Prostate cancer in Ottawa Prostate cancer in Winnipeg Prostate cancer in Quebec City Prostate cancer in Hamilton Prostate cancer in Kitchener Prostate cancer in London Prostate cancer in Halifax Prostate cancer in New York Prostate cancer in Los Angeles Prostate cancer in Chicago Prostate cancer in Houston

Other conditions

Acne Vitiligo Hidradenitis suppurativa Rosacea Alopecia areata Endometriosis Uterine fibroids Menopause Infertility Erectile dysfunction Enlarged prostate (BPH) Breast cancer Lung cancer Non-small cell lung cancer Colorectal cancer Pancreatic cancer Ovarian cancer Melanoma Leukemia Lymphoma Multiple myeloma Bladder cancer Kidney cancer Liver cancer